Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTM7WCE)

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This DTT

3 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ATI-2042	DMWP59B	Atrial fibrillation	BC81.3	Phase 2	[2]
AZD-2927	DM6AI9N	Atrial fibrillation	BC81.3	Phase 2	[3]
Lu-AA39959	DM34FWR	Bipolar disorder	6A60	Phase 2	[1]
------------------------------------------------------------------------------------

2 Discontinued Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lu-AA38466	DMGUX5Y	Neurological disorder	6B60	Discontinued in Phase 1	[4]
AZD-0902	DMS7INR	Chronic obstructive pulmonary disease	CA22	Terminated	[5]
------------------------------------------------------------------------------------

References

1	Lundbeck: leading the way in the treatment of CNS disorders.
2	A randomized trial of budiodarone in paroxysmal atrial fibrillation. J Interv Card Electrophysiol. 2012 Jun;34(1):1-9.
3	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7704).
4	Lundbeck is developing new and promising pharmaceuticals for the treatment of depression, anxiety and psychotic disorders and for new disease areas such as stroke and alcohol dependence. Pipeline report of Lundbeck in 2008.
5	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019129)